Sarepta Therapeutics (SRPT) Non-Current Debt (2010 - 2026)

Sarepta Therapeutics' Non-Current Debt history runs 17 years deep, the most recent figure standing at $838.2 million for Q1 2026.

• In Q1 2026, Non-Current Debt fell 26.37% year-over-year to $838.2 million; the TTM figure through Mar 2026 stood at $838.2 million (down 26.37% YoY), while the FY2025 annual figure was $829.0 million, down 27.1% from the prior year.
• Non-Current Debt for Q1 2026 stood at $838.2 million, up from $829.0 million in the prior quarter.
• The five-year high for Non-Current Debt was $1.5 billion in Q4 2022, with the low at $829.0 million in Q4 2025.
• The 5-year median for Non-Current Debt is $1.1 billion (2025), against an average of $1.2 billion.
• The sharpest annual moves came in 2022 and 2025: Non-Current Debt surged 173.97% in 2022, then retreated 27.1% in 2025.
• Sarepta Therapeutics' Non-Current Debt stood at $1.5 billion in 2022, then decreased by 19.83% to $1.2 billion in 2023, then declined by 8.15% to $1.1 billion in 2024, then dropped by 27.1% to $829.0 million in 2025, then gained by 1.11% to $838.2 million in 2026.
• Business Quant data shows SRPT's Non-Current Debt at $838.2 million in Q1 2026, $829.0 million in Q4 2025, and $1.0 billion in Q3 2025.